Amarin reported $0 in Loan Capital for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
DBV Technologies DBVT:US 0 0
Abbvie ABBV:US $ 63522M 667M
Aerie Pharmaceuticals AERI:US $ 311.68M 77.15M
Alnylam Pharmaceuticals ALNY:US $ 676.71M 1.01M
Amarin AMRN:US $ 0M 0M
AstraZeneca AZN:LN 28805M 83M
Biocryst Pharmaceuticals BCRX:US $ 604.46M 19M
Epizyme EPZM:US $ 232.49M 379K
Esperion Therapeutics ESPR:US $ 258.68M 398K
GlaxoSmithKline GSK:LN 29226M 8654M
Halozyme Therapeutics HALO:US $ 788.1M 0.84M
Heron Therapeutics HRTX:US $ 149.13M 0.05M
Intercept Pharmaceuticals ICPT:US $ 716.88M 177.1M
JAZZ PHA JAZZ:US $ 5992.87M 32.34M
Novartis NOVN:VX SF 24373M 150M
Teva Pharmaceutical Industries TEVA:US $ 20840M 777M